<DOC>
	<DOCNO>NCT01373463</DOCNO>
	<brief_summary>This study open patient diagnose non-squamous Stage III Non Small Cell Lung Cancer ( NSCLC ) surgery remove tumor . The purpose study : - Test combination two chemotherapeutic drug along radiation therapy , give prior surgery see effect ( good bad ) someone type cancer . Chemotherapeutic drug selectively destroy diseased cancer cell tissue . - Test safety different dose level radiation give combination chemotherapy ; - Determine side effect associate combine radiation two chemotherapy combination .</brief_summary>
	<brief_title>Cisplatin Pemetrexed With Radiation Followed Lobectomy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm nonsquamous NSCLC . Resectable T3 , N2 disease ( T3N1 , resectable T13N2 multistation nonbulky nodal station 2 cm preoperative workup , T4N01 Resectable T3 include patient satellite lesion lobe primary . Male Female , age &gt; = 18 year able give inform consent . Tumor technically operable lobectomy , bilobectomy sleeve resection . Patient medically operable ECOG Performance Status 0 1 . Adequate bone marrow , hepatic renal function assess within 28 day Signed informed consent . Women childbearing potential negative pregnancy test prior enrollment study . Men partner childbearing age group woman childbearing potential must use effective contraception treatment 6 month thereafter . The ability interrupt NSAIDS 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration Pemetrexed . The ability take folic acid , Vitamin B12 , dexamethasone accord protocol . Patients must negative MRI CT Scan brain . Patients chemotherapy radiation therapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier . Patients may receive investigational agent . History allergic reaction attribute compound agent use study . Pregnant lactate woman . Male patient female sexual partner reproductive age group refuse use effective method contraception exclude trial . Patients concurrent serious infection . Patients unstable serious concurrent medical condition exclude . Presence third space fluid control drainage . Weight loss &gt; 10 percent baseline weight . HIVpositive patient combination antiretroviral therapy ineligible Patients hypercalcemia exclude . Patients require pneumonectomy exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>resectable</keyword>
</DOC>